Industry Briefs: Feb. 13, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry Briefs: Feb. 13, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.


Company News

Bend Research has entered into a licensing agreement with Eli Lilly, under which Bend Research will make its proprietary spray-dried dispersion technology available to Lilly. Read More

BioDiem has licensed its live attenuated influenza virus (LAIV) vaccine technology to China-based Changchun BCHT Biotechnology. Read More

Carbogen Amcis has announced that its Bubendorf, Switzerland, API-manufacturing site has successfully completed a September 2011 FDA cGMP inspection. Read More

Discovery Labs has entered into a definitive agreement with Lacey Manufacturing, a unit of Precision Engineered Products, to manufacture and supply product for the commercial introduction of Afectair, a series of proprietary ventilator circuit–patient interface connectors and related componentry for the delivery of inhaled therapies to patients requiring ventilatory support. Read More

Quintiles has launched two services—Strategic Drug Development and Consulting at Quintiles—for the development and commercialization of new medications in Asia. Read More

Valeant Pharmaceuticals has agreed to acquire the ophthalmic biotechnology company Eyetech. Read More

People News

Cobra Biologics has appointed Sharon Brownlow and Partick Lansky as business development managers, and added nonexecutive directors Elisabeth Lindner, Carl Johan Sundberg, and Jinyue Wang, to its board. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
30%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans

Click here